![icad stroke icad stroke](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/9253a4b2-5820-459e-a036-da631e4d633a/yjscd3600-fig-0001.jpg)
5, 6 In the US annually, there are approxi-mately 750,000 strokes and an additional 250,000 TIAs. There was a higher rate of intracranial disease in Afri-can-American, Japanese, Chinese, and His-panic patients, 3, 4 and conversely higher rates of extracranial disease in Caucasians. Mortality rates at 100 days for these 3 groups were dismal at 10.1%, 21.4%, and 44.7%, respectively. Intracranial atherosclerotic disease (ICAD) accounts for 10-15 of. 2 They found isolated symptomatic intracranial stenosis>50 % in 6.5 % of patients, proximal middle cerebral artery occlusion in 3.7 % and basilar artery occlusion in 1.2%. Ischemic stroke is a major cause of morbidity and mortality, incurring significant cost. EPIDEMIOLOGY ICAD accounts for approximately 5 to 10 % of all strokes and transient ischemic attacks (TIAs).1 Among the more specific studies, the German Stroke Study Collabo-ration prospectively identified 4157 patients over 20 months at 11 different centers who were admitted within 24 hours of, new acute ischemic symptoms. In this article, we review the epidemiology, natural history, im-aging, and treatment of ICAD. While we are proposing future studies to reduce recurrent ICAD stroke risk, it should be noted that, in the long term, our research may lead to effective primary ICAD stroke risk reduction through PCSK9 inhibition in patients at high risk of.
#Icad stroke trial
While the optimal treatment paradigm for ICAD is unknown, endovascular techniques (angioplasty and stenting) can be safely done that may reduce stroke rates in ap-propriately selected patients. Such a trial would provide evidence for the utility of alirocumab to prevent recurrent stroke in ICAD. In addition, it is known which subgroups that are at the highest risk of subse-quent stroke. Atrial Fibrillation Known Before or Detected After Stroke Share Similar Risk of. However, noninvasive techniques including transcranial ultrasound and MRA are now emerging as reliable modalities to exclude. For diagnosis of ICAD, intra-arterial angiography is the gold standard to identify extent of stenosis. Approximately half of those affected are Asians. Once thought to be uncommon, it is now known that ICAD is almost as com-mon as extracranial (cervical) carotid athero-sclerotic disease. Intracranial atherosclerotic disease (ICAD) is the most common proximate mechanism of ischemic stroke worldwide. Over the past decade, there has been a marked awareness of the epidemiology, clini-cal severity and treatment options for patients with Intracranial Atherosclerotic disease (ICAD).